GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of
by Selina McKee
www.pharmatimes.com/news/gw_completes_epidiolex_submission_1209905The Mundipharma network of independent associated companies says European regulators have approved use of Pelmeg, a biosimilar of Amgen’s white blood cell booster Neulasta. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/eu_oks_mundipharmas_neulasta_biosimilar_1265039Takeda has put forward a new proposed bid for Shire, increasing the cash portion of the deal. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/takeda_ups_its_offer_for_shire_1232830London, UK-based Arix Bioscience has entered into a strategic agreement with French drugmaker Ipsen to develop and commercialise innovative therapies. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/arix_ties_with_ipsen_1223364Takeda says it has received unconditional clearance from the US Federal Trade Commission for the proposed acquisition of Shire. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/takeda_gets_us_nod_for_shire_buy_1243748AstraZeneca has completed its $2.7-billion acquisition of ZS Pharma, bolstering its cardiovascular and metabolic disease portfolio. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_completes_acquisition_of_zs_pharma_972294Sanofi Pasteur and MSD have announced the end of their European vaccines joint venture so that their own “distinct growth strategies” can be pursued instead. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/sanofi,_msd_to_dismantle_vaccines_jv_1020306A new clinical study has found that Kaia Health’s artificial intelligence app successfully decreases symptoms of Chronic Obstructive Pulmonary Disease (COPD). - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/ai_app_decreases_symptoms_of_copd,_study_finds_1272387NHS Confederation chief executive Niall Dickson is warning that the NHS is “under intolerable strain”, after the latest performance data continue to show growing demand and missed targets. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/nhs_under_intolerable_strain_1244161The UK’s Shield Therapeutics has successfully submitted an application to market iron deficiency therapy Feraccru in the US. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shield_files_feraccru_with_the_fda_1254055
